This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Akoya Biosciences Showcases Spatial Biology 2.0 Solutions At AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale CI
JPMorgan Adjusts Price Target on Akoya Biosciences to $10 From $12, Maintains Overweight Rating MT
UBS Adjusts Akoya Biosciences Price Target to $7.50 From $7, Maintains Buy Rating MT
Akoya Biosciences, Inc. Provides Revenue Guidance for the Full Year 2024 CI
Transcript : Akoya Biosciences, Inc., Q4 2023 Earnings Call, Mar 04, 2024
Earnings Flash (AKYA) AKOYA BIOSCIENCES Posts Q4 Revenue $26.5M, vs. Street Est of $26.1M MT
Akoya Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Transcript : Akoya Biosciences, Inc. - Special Call
Transcript : Akoya Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 03:45 PM
Akoya Biosciences, Inc. Announces Board Changes CI
Akoya Biosciences Shares Jump on 2024 Outlook, Thermo Fisher Deal DJ
Akoya Biosciences Expects 20% Revenue Growth in 2024; Shares Gain Premarket MT
Akoya Biosciences Unveils Algorithm for Integration of Spatial, Single-Cell Data; Shares Jump Premarket MT
Akoya Biosciences Deploys the Maxfuse Algorithm Co-Developed by Dr. Garry Nolan and His Laboratory At Stanford University for Multiomic Integration of Spatial and Single-Cell Data on the Enable Medicine Platform CI
Akoya Biosciences, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023 and for the Fiscal Year 2024 CI
Akoya Biosciences, Inc. and Thermo Fisher Scientific, Inc. Announce License and Distribution Agreement to Deliver Spatial Multiomics Workflow CI
Stephens Adjusts Price Target on Akoya Biosciences to $9 From $14, Maintains Overweight Rating MT
Transcript : Akoya Biosciences, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Akoya Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (AKYA) AKOYA BIOSCIENCES Posts Q3 Revenue $25.2M, vs. Street Est of $24.5M MT
Akoya Biosciences, Inc. Reiterates Revenue Guidance for the Fiscal Year 2023 CI
Akoya Biosciences to Showcase New Spatial Biology 2.0 Solutions and Spatial Phenotyping Data at SITC 2023 CI
Morgan Stanley Adjusts Akoya Biosciences' Price Target to $8 From $15, Keeps Overweight Rating MT
UBS Cuts Akoya Biosciences Price Target to $7 From $12, Maintains Buy Rating MT
Chart Akoya Biosciences, Inc.
More charts
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery, clinical research, and diagnostics. It offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. It offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.9 USD
Average target price
9 USD
Spread / Average Target
+130.77%
Consensus
  1. Stock Market
  2. Equities
  3. AKYA Stock
  4. News Akoya Biosciences, Inc.
  5. Akoya Biosciences : JPMorgan Starts Akoya Biosciences at Overweight With $23 Price Target